Quick Summary

Sweet Clover (Melilotus officinalis) is a leguminous plant traditionally used and currently under research for diverse health-related applications. It contains bioactive compounds such as coumarins and flavonoids, which have been associated with anti-inflammatory, antioxidant, and vascular health properties. Clinical evidence specifically on Sweet Clover includes limited pharmacological trials and studies investigating its use as part of combination therapies, particularly for vascular conditions and as an adjunct in wound healing.

What Is It?

Sweet Clover is a flowering leguminous herbaceous plant known scientifically as Melilotus officinalis. It has been utilized in traditional medicine, and recent scientific interest focuses on its bioactive constituents and possible health effects. The plant is rich in coumarins and flavonoids, compounds that may contribute to its medicinal properties.

Traditional Uses

Traditionally, Sweet Clover has been used for various purposes including improving vascular health and supporting wound healing. It is often included in herbal mixtures targeting circulatory issues and skin repair. Although widely used in folk medicine, clinical confirmation of these uses remains limited.

Active Compounds

  • Coumarins – compounds under investigation for antioxidant and anti-inflammatory effects
  • Flavonoids such as isoquercetin – linked to wound healing mechanisms

Potential Benefits with Evidence Levels

  • Possible symptomatic improvement in chronic venous disease
    Evidence level: Expert consensus and low-certainty clinical evidence.
    Details: Sweet Clover was included in an oral fixed-dose combination with other venoactive nutraceuticals considered a reasonable first-line conservative option by Italian vascular specialists (Buso et al., 2025). Clinical trials showed no clear advantage over balneotherapy for pain or edema but evidence certainty is very low (de Moraes Silva et al., 2023).
  • Potential adjunctive use in wound healing including diabetic foot ulcers
    Evidence level: Preliminary clinical evidence and systematic review.
    Details: Isoquercetin in Sweet Clover is implicated in processes like angiogenesis and epithelialization. Systematic reviews identify the herb among botanicals reported to aid diabetic foot ulcer healing, though high-quality randomized controlled trials specifically on Sweet Clover are lacking (Narzary et al., 2023; Zamanifard et al., 2024).
  • Anti-inflammatory and antioxidant effects
    Evidence level: Preclinical research and traditional knowledge.
    Details: Coumarins in Sweet Clover have demonstrated antioxidant and anti-inflammatory activity in molecular studies relevant to vascular and metabolic disorders; however, clinical evidence remains limited (Mostafa et al., 2025; Lewandowska & Majewski, 2025).

Side Effects

Currently, no strong clinical evidence attributes specific adverse effects directly to Sweet Clover. Studies involving combinations including Sweet Clover suggest no significant increase in adverse events compared to controls. Reported complications in related trials (e.g., erysipelas, thromboembolic events, palpitations) were not conclusively linked to Sweet Clover itself (de Moraes Silva et al., 2023).

Drug Interactions

No direct clinical studies have been reported on drug interactions specific to Sweet Clover. However, due to its coumarin content, potential interactions with anticoagulant medications such as warfarin are plausible based on existing herb-warfarin interaction literature. Cautious use is recommended when Sweet Clover is taken alongside anticoagulant or antiplatelet drugs pending further research.

Who Should Avoid It

Specific contraindications for Sweet Clover are not well-defined in the current evidence. Standard precautions applicable to coumarin-containing herbs should be observed, especially for individuals with bleeding disorders or those taking blood-thinning medications. Additionally, due to insufficient safety data, use during pregnancy and breastfeeding is not recommended without medical supervision.

Evidence Limitations

  • Most clinical studies involve Sweet Clover as part of combination therapies rather than as a standalone treatment.
  • There is a limited number of randomized controlled trials specifically investigating the efficacy and safety of Sweet Clover.
  • Some clinical evidence is of low to very low certainty due to small sample sizes, lack of blinding, and heterogeneous outcomes.
  • Mechanistic insights mainly derive from preclinical and in vitro studies; robust clinical translation is pending.
  • Data on drug interactions and contraindications are sparse, necessitating cautious interpretation and use.

References

  • Buso G, Santini P, Ghirardini F, Bigolin P, Martini R, On Behalf Of The Siapav Working Group On Venoactive Nutraceuticals. (2025). Delphi Consensus on the Role of Venoactive Nutraceuticals in the Management of Chronic Venous Disease: A Position Statement of the Italian Society of Angiology and Vascular Medicine (SIAPAV). PMC12735476.
  • de Moraes Silva MA, Nakano LC, Cisneros LL, Miranda F. (2023). Balneotherapy for chronic venous insufficiency. PMC9828836. doi:10.1002/14651858.cd013085.pub3
  • Narzary I, Swarnakar A, Kalita M, Middha SK, Usha T, Babu D, et al. (2023). Acknowledging the use of botanicals to treat diabetic foot ulcer during the 21st century: A systematic review. PMC10303622. doi:10.12998/wjcc.v11.i17.4035
  • Zamanifard M, Nasiri M, Yarahmadi F, Zonoori S, Razani O, Salajegheh Z, et al. (2024). Healing of diabetic foot ulcer with topical and oral administrations of herbal products: A systematic review and meta-analysis of randomized controlled trials. PMC10867296. doi:10.1111/iwj.14760
  • Mostafa RE, Ali DE, El-Shiekh RA, El-Alfy AN, Hafeez MSAE, Reda AM, Fayek NM. (2025). Therapeutic applications of natural products in the management of venous diseases: a comprehensive review. PMC11992006. doi:10.1007/s10787-025-01688-z
  • Lewandowska K, Majewski MS. (2025). The Involvement of Epilobium parviflorum in Different Human Diseases, with Particular Attention to Its Antioxidant and Anti-Inflammatory Properties and Benefits to Vascular Health. PMC12073485. doi:10.3390/nu17091577

Last Reviewed

2025

Disclaimer: This information is provided for educational purposes and does not constitute medical advice. Sweet Clover and its extracts have not been approved by regulatory authorities for the treatment or prevention of any medical condition. Consult a healthcare professional before using Sweet Clover, especially if you are pregnant, breastfeeding, have a medical condition, or are taking other medications.